V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10373365 | 10043065 | 1.56 | 0 | Disease modification (D) | 2019-06-18 | 2019-07-10 | Cabazitaxel | 2 | N | CYCLOPHOSPHAMIDE | 100640933 |
| 10373969 | 10043067 | 1.72 | 80 | Palliative (P) | 2019-03-30 | 2019-04-13 | FLUOROURACIL + IRINOTECAN | 02 | N | BLEOMYCIN + CYCLOPHOSPHAMIDE + ETOPOSIDE + MITOXANTRONE + PROCARBAZINE + VINBLASTINE | 100384026 |
| 10375316 | 10043068 | 1.75 | 100.2 | null | 2019-11-18 | 2019-12-06 | RCEOP | 02 | null | BLEOMYCIN + DACARBAZINE + DOXORUBICIN + VINBLASTINE | 100612893 |
| 10377518 | 10043069 | 1.68 | 71.2 | null | 2018-05-25 | 2018-05-25 | PACLITAXEL + TRASTUZUMAB | 02 | null | CARBOPLATIN + DOCETAXEL + TRASTUZUMAB | 100064549 |
| 10381938 | 10043072 | 1.85 | 86.9 | Curative (C) | 2019-01-07 | 2019-01-19 | BORTEZOMIB + DARATUMUMAB + THALIDOMIDE | 02 | N | CARBOPLATIN + PACLITAXEL + PEMBROLIZUMAB | 101748891 |
| 10384782 | 10043074 | 1.72 | 79 | Palliative (P) | 2019-01-30 | 2019-02-02 | CARBOPLATIN + DOCETAXEL + Pertuzumab + Trastuzumab | 02 | N | CYCLOPHOSPHAMIDE + ETOPOSIDE + RITUXIMAB + VINCRISTINE | 100920432 |
| 10388425 | 10043077 | 1.57 | 101.3 | 03 | 2017-01-30 | 2017-02-09 | Ribociclib | 02 | N | IDELALISIB | 100843694 |
| 10388861 | 10043078 | 1.62 | 78.6 | Neo-adjuvant (N) | 2018-07-11 | 2018-07-19 | null | 02 | N | MELPHALAN | 101616462 |
| 10389528 | 10043079 | 1.72 | 73.7 | Curative (C) | 2016-09-02 | 2016-09-03 | IDELALISIB + RITUXIMAB | 02 | N | MELPHALAN | 101248608 |
| 10390456 | 10043083 | 1.66 | 55 | Palliative (P) | 2020-02-28 | 2020-03-11 | Liposomal Doxorubicin 50mg/m2 | 02 | N | SCOPE 1 TRIAL | 100258941 |
| 10391097 | 10043084 | 0 | null | 03 | 2019-12-01 | 2019-12-01 | Olaparib | 02 | N | CYTARABINE + DAUNORUBICIN | 101266589 |
| 10393976 | 10043089 | 1.67 | 0 | Palliative (P) | 2018-07-28 | 2018-07-28 | Ixazomib + Lenalidomide | 02 | N | OXALIPLATIN + MDG | 101836180 |
| 10395755 | 10043093 | null | null | null | 2019-07-05 | 2019-07-10 | ESHAP | null | null | CISPLATIN + ETOPOSIDE | 100414067 |
| 10400916 | 10043101 | 1.76 | 67 | Curative (C) | null | 2018-07-17 | CTD | null | N | BORTEZOMIB + DARATUMUMAB + THALIDOMIDE | 101663084 |
| 10405521 | 10043108 | 1.56 | 0 | 03 | 2016-06-01 | 2018-12-29 | Obinutuzumab +CVP | 02 | N | PEG INTERFERON | 101438017 |
| 10406530 | 10043111 | 1.81 | 75.45 | Curative (C) | 2017-08-29 | 2017-09-13 | Letrozole + Ribociclib | 02 | N | BRIGATINIB | 100252882 |
| 10406580 | 10043112 | 1.74 | 62 | Palliative (P) | 2019-02-09 | 2019-02-23 | Carboplatin + Paclitaxel + Pembrolizumab | 02 | N | BENDAMUSTINE + POLATUZUMAB VEDOTIN + RITUXIMAB | 101412665 |
| 10407616 | 10043116 | 1.8 | 93.6 | 03 | 2019-07-18 | 2019-07-23 | Ixazomib + Lenalidomide | 02 | null | PRISM TRIAL | 100748066 |
| 10407907 | 10043117 | 1.75 | 75 | 03 | 2017-11-18 | 2017-11-27 | Bexarotene | 02 | N | LUTETIUM-177 | 100734335 |
| 10409217 | 10043118 | null | 68.2 | 03 | 2018-09-26 | 2018-10-24 | Sorafenib | N | null | BLEOMYCIN + DACARBAZINE + DOXORUBICIN + VINBLASTINE | 101473163 |
| 10410681 | 10043122 | 1.67 | 70 | Adjuvant (A) | 2019-01-07 | 2019-07-26 | GemCarbo Days 1+8 | N | N | ACTICCA-1 TRIAL | 101547218 |
| 10410721 | 10043123 | 1.65 | 100 | Curative (C) | 2019-10-08 | 2019-11-04 | FLAIR trial | 02 | N | CAPECITABINE + MITOMYCIN + RT | 101109753 |
| 10413699 | 10043126 | 1.65 | 70.7 | 03 | 2019-02-28 | 2019-02-28 | Cisplatin + Docetaxel +Fluorouracil | 02 | null | ICON8B TRIAL | 100958792 |
| 10417622 | 10043129 | 1.54 | 64 | null | 2020-11-03 | 2020-11-03 | Bortezomib + Cyclophos + Dex | 02 | null | CYCLOPHOSPHAMIDE + DOCETAXEL + EPIRUBICIN | 101605680 |
| 10418705 | 10043130 | 1.73 | 84.35 | null | 2019-11-02 | 2019-11-02 | Carboplatin + Liposomal Doxorubicin | 02 | null | CARBOPLATIN + FLUOROURACIL | 101159646 |
| 10419082 | 10043131 | 1.83 | 89.4 | null | 2021-12-25 | 2021-12-28 | Capecitabine 35days + RT | N | N | CISPLATIN + CAPECITABINE + EPIRUBICIN | 100296997 |
| 10421790 | 10043135 | 1.76 | 82.2 | Curative (C) | 2019-05-04 | 2019-05-17 | Ixazomib + Lenalidomide | null | null | ALEMTUZUMAB | 100885565 |
| 10428682 | 10043143 | 1.65 | 66 | null | 2022-04-20 | 2022-05-02 | null | 02 | null | LETROZOLE + PALBOCICLIB | 101230157 |
| 10429245 | 10043144 | 1.57 | 60.9 | Curative (C) | 2022-01-29 | 2022-03-27 | ECX | 02 | null | FEC + DOCETAXEL | 101686829 |
| 10430936 | 10043146 | 0 | null | Curative (C) | 2018-10-28 | 2018-10-29 | null | 99 | null | STAMPEDE TRIAL | 100526116 |
| 10431345 | 10043148 | 1.69 | 68.1 | Curative (C) | 2017-10-07 | 2017-10-07 | Letrozole + Palbociclib | 2 | N | SORAFENIB | 101540212 |
| 10432764 | 10043150 | null | null | Palliative (P) | 2018-05-24 | 2018-05-24 | ABVD | 02 | Y | CARBOPLATIN + DOCETAXEL + TRASTUZUMAB | 101502651 |
| 10433066 | 10043151 | 1.71 | 51.9 | Palliative (P) | 2017-09-10 | 2017-10-29 | Ixazomib + Lenalidomide | 02 | N | CHLORAMBUCIL + PROCARBAZINE + VINBLASTINE | 100883142 |
| 10435685 | 10043153 | 1.63 | 72 | Disease modification (D) | 2019-04-17 | 2019-04-17 | CETUXIMAB + IRINOTECAN + MDG | N | N | CARFILZOMIB | 101680680 |
| 10438537 | 10043156 | 1.55 | 110.9 | Disease modification (D) | 2018-09-25 | 2018-09-28 | AC | N | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 101433161 |
| 10440335 | 10043160 | 1.59 | 83 | Curative (C) | 2019-11-28 | 2019-11-29 | Bortezomib + Panobinostat | 2 | null | CISPLATIN + ETOPOSIDE | 101048389 |
| 10441709 | 10043161 | null | 79.4 | null | 2022-02-25 | 2022-02-27 | Melphalan oral | 02 | null | THALIDOMIDE | 100869630 |
| 10443120 | 10043163 | 1.65 | 75.8 | Disease modification (D) | null | 2021-06-08 | Tivozanib | N | N | ABVD | 100256812 |
| 10444398 | 10043165 | 1.38 | 0 | null | 2018-07-15 | 2018-07-22 | Alemtuzumab | 02 | N | FLUDARABINE + MITOXANTRONE | 100255588 |
| 10444815 | 10043166 | 1.6 | 59.4 | Curative (C) | 2020-03-07 | 2020-03-14 | PENTOSTATIN + RITUXIMAB | N | null | PERTUZUMAB + TRASTUZUMAB | 101713521 |
| 10446586 | 10043167 | 1.85 | 79.2 | Curative (C) | 2020-11-10 | 2020-11-21 | Bortezomib + MELPHALAN | 02 | N | BLEOMYCIN + CYCLOPHOSPHAMIDE + ETOPOSIDE + MITOXANTRONE + VINCRISTINE | 101407014 |
| 10448066 | 10043168 | 1.64 | 68.2 | Palliative (P) | 2017-11-01 | 2017-11-23 | Bortezomib + Cyclophos + Dex | N | N | NILOTINIB | 100529486 |
| 10451628 | 10043170 | 1.64 | 55.7 | Palliative (P) | 2019-09-21 | 2019-11-21 | null | 02 | Y | ANTI-THYMOCYTE GLOBULIN | 101459943 |
| 10451760 | 10043171 | 1.62 | 88.6 | null | 2022-02-26 | 2022-03-04 | Cisplatin + Docetaxel +Fluorouracil | 02 | null | ANAGRELIDE | 100654333 |
| 10453120 | 10043174 | 1.6 | 86.6 | Palliative (P) | 2016-12-09 | 2016-12-28 | AXITINIB | 02 | null | CISPLATIN + RT | 101099372 |
| 10453660 | 10043175 | 1.75 | 74.8 | Palliative (P) | 2016-06-25 | 2016-06-27 | null | 02 | N | THALIDOMIDE | 101746091 |
| 10456006 | 10043176 | 1.56 | 100.9 | Curative (C) | 2018-02-10 | 2018-02-15 | Bortezomib + CYCLOPHOSPHAMIDE | 02 | null | CVD | 101235963 |
| 10456028 | 10043177 | 1.81 | 101 | Palliative (P) | 2019-10-02 | 2019-10-12 | CTD Attenuated (Thalidomide 200mg) | null | N | OFATUMUMAB | 100139223 |
| 10457463 | 10043178 | 1.86 | 64.3 | Neo-adjuvant (N) | 2018-06-08 | 2018-06-11 | CAPECITABINE + PACLITAXEL | 02 | N | SORAFENIB | 101639886 |
| 10458298 | 10043179 | 1.68 | 66.4 | 03 | 2019-09-15 | 2019-10-06 | MPV (cycle 1-4) | 02 | null | CARBOPLATIN + PACLITAXEL + PEMBROLIZUMAB | 101103577 |